BioSpace News Archive

Mezzion Pharma (“Mezzion”) announced that it has secured nearly $40M USD to fund FUEL-2, their confirmatory phase 3 clinical trial, along with future commercialization and regulatory submissions in other countries including Europe.

Fe Pharmaceuticals has raised a SEED investment to continue developing DIBI, a non-toxic, iron-binding copolymer, as a potent, broad-spectrum, antimicrobial agent active against bacterial and fungal infections, including drug-resistant organisms and as a potential anti-inflammatory and cancer therapy.

Hospital for Special Surgery has received the Press Ganey Guardian of Excellence® award for the 10th consecutive year in the category of “patient experience.” Press Ganey is a national company that measures healthcare performance to improve quality of care.

Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved QALSODY™ (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene.

Kaiser Permanente announced that Narayanan “Nari” Gopala has been promoted to chief digital officer for Kaiser Foundation Health Plan and Hospitals.

The Muscular Dystrophy Association (MDA) celebrates the US Food and Drug Administration (FDA) accelerated approval of Qalsody (tofersen), for the treatment of amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig’s disease) associated with mutation in the superoxide dismutase 1 (SOD1) gene (SOD1-ALS).

Galapagos NV announces the approval of all resolutions proposed at its annual shareholders’ meeting held today at 14.00 CET.

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT) today announced it will be participating in the upcoming BofA Securities Healthcare Conference in Las Vegas, Nevada.

Arcutis Biotherapeutics, Inc., an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, announced that it will host a conference call and webcast at 4:30 p.m. ET on Tuesday, May 9, 2023, to report its first quarter financial results.

Invivyd, Inc. announced that David Hering, chief executive officer of Invivyd, is scheduled to present in a fireside chat at H.C. Wainwright’s BioConnect Investor Conference on Tuesday, May 2, 2023 at 4:00 p.m. ET at the Nasdaq World Headquarters in New York, NY.